Eli Lilly and Company

“Eli Lilly is one of the finest pharmaceutical franchises in modern history — tirzepatide's dual-agonist superiority, 82% gross margins, accelerating ROIC, and a decade-plus reinvestment runway in the GLP-1/incretin category make it a genuine compounding engine. However, at a ~$980B market cap and a probability-weighted 5-year CAGR of approximately 6%, the stock prices in near-perfection and leaves essentially no margin of safety against the singular credible risk: US drug pricing policy reform that could structurally compress GLP-1 net revenues post-2027. The business earns a 9.2; the valuation earns a 3.5. The right action is to track this closely and be prepared to act aggressively on a 30-40% drawdown driven by cyclical or policy-driven volatility — that is when this exceptional business becomes an exceptional investment.”